An effortless and comprehensive approach to burden of illness reviews
Published: 26-03-2018
We searched the heoro.com database for cost and resource use studies in acute myeloid leukaemia published between 1960 and 5th December 2017, and analysed the results obtained to determine the direct and indirect costs and resource use cited across an array of geographical locations, populations and interventions.
We present the result as an Evidence Map, which can be downloaded here. To use the Map, open it in Microsoft Excel and enable macros.
A total of 78 abstracts were found to report cost and resource use in Acute Myeloid Leukaemia. Of these abstracts, 61 reported direct costs and 13 reported indirect costs. A total of 23 papers reported resource use and 5 remained unclear. The USA was the most frequently cited location (20 abstracts) followed by the Netherlands (8), the UK (7), Canada (6) and France (6).
Studies reporting cost and resource use in AML: geographical location by information reported.
A total of 59 different intervention methods were identified which were categorised into 12 categories, of which conventional chemotherapy was the most popular intervention type (26 abstracts), followed by stem cell therapy (16) and colony-stimulating factors (13). Other interventions include mitoxantrone, enocitabine and azacytidine. Whilst most abstracts (49) recruited general members of the acute myeloid leukaemia population, some included specific populations. Ten abstracts cited the used of adults, 11 assessed an elderly population and 5 evaluated children, while 6 did not specify a population type.
Studies reporting cost and resource use in AML: population by intervention type
23 papers were published before 2000, 25 between 2000 and 2009, and 30 between 2010 and 2017.
Studies reporting cost and resource use in AML: Year of publication
Economic burden studies in acute myeloid leukaemia have most commonly explored the direct costs associated with chemotherapy and interventions to prevent adverse events associated with chemotherapy. A minority of studies reported indirect costs or explored the economic burden specifically in children.
You can download a free copy of the Evidence Map here.
Written and Created by Alexandra Furber
Research assistant at Crystallise